• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZONG Huiying,ZHANG Yundi,LI Yue,LI Yan.Optimization of individualized tacrolimus dosing regimen after liver transplantation based on genetic testing and blood concentration monitoring techniques[J].Journal Of Pharmaceutical Research,2024,43(2):194-199[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3088times   Download 2703次 QR Code for this article
Scan with your phone!
基于基因检测和血药浓度监测技术优化肝移植术后他克莫司个体化给药方案
宗慧颖1,2,张云迪1,2,李越2,李妍2
Font:Larger+|Default|Smaller-
(1.山东中医药大学,山东 济南 250355;2.山东第一医科大学第一附属医院<山东省千佛山医院>,山东 济南 250014)
摘要:
他克莫司是广泛应用于临床的钙调神经磷酸酶类抑制剂,被作为肝移植术后预防和治疗急性排斥反应的一线药物。然而,在临床应用中,他克莫司表现出治疗窗口窄、药动学个体差异大等特点,移植后早期低浓度的他克莫司可能会诱发排斥反应;而高浓度的他克莫司可能会导致肾毒性和/或神经毒性,因此对于他克莫司药动学的影响因素进行深入研究至关重要。本文通过检索中国知网(CNKI)、维普、万方以及PubMed数据库,综述了临床上对患者实行基因检测和血药浓度监测的必要性,得出根据基因多态性进行给药以及寻找替代药时曲线下面积的最佳采样点策略可能将有助于临床医生对他克莫司的最佳起始剂量进行预测,进而帮助调整维持方案,且有望减少不良反应的发生。
关键词:  肝移植  他克莫司  基因检测  血药浓度监测
DOI:10.13506/j.cnki.jpr.2024.02.016
基金项目:山东省医学会齐鲁专项(No.YXH2022ZX02048)
Optimization of individualized tacrolimus dosing regimen after liver transplantation based on genetic testing and blood concentration monitoring techniques
ZONG Huiying1,2,ZHANG Yundi1,2,LI Yue2,LI Yan2
(1. Department of Pharmacy, Shandong University of Traditional Chinese Medicine, Department of Pharmacy, Shandong Provincial Qianfoshan Hospital Jinan 250355, China; 2. Clinical Pharmacy, the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China)
Abstract:
Tacrolimus, a widely used clinical calcium-modulated neural phosphatase inhibitor, is used as a first-line agent for the prevention and treatment of acute rejection after liver transplantation. However, in clinical applications, tacrolimus exhibits a narrow therapeutic window and large individual differences in pharmacokinetics, and low concentrations of tacrolimus in the early post-transplant period may induce rejection; whereas high concentrations of tacrolimus may lead to nephrotoxicity and/or neurotoxicity, so in-depth studies on the factors influencing the pharmacokinetics of tacrolimus are essential. In this article, we reviewed the clinical need for genetic testing and blood concentration monitoring in patients by searching the Chinese Network of Knowledge (CNKI), Wipro, Wanfang, and PubMed databases, and concluded that dosing based on genetic polymorphisms and the strategy of finding the optimal sampling point of the area under the curve at the time of substitution may be helpful to clinicians in predicting the optimal starting dosage of tacrolimus, which can help in the adjustment of the maintenance regimen, and is expected to reduce the incidence of adverse effects.
Key words:  Liver transplantation  Tacrolimus  Genetic testing  Blood concentration monitoring
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.